1,241 filings
6-K
SNY
Sanofi
25 Apr 24
Sales growth of 6.7% at CER and business EPS(1) of €1.78
10:49am
F-3ASR
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
S-8
SNY
Sanofi
4 Apr 24
Registration of securities for employees
8:45am
6-K
SNY
Sanofi
20 Mar 24
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
2:07pm
S-8 POS
SNY
Sanofi
15 Mar 24
Registration of securities for employees (post-effective amendment)
8:40am
6-K
t587r76o
27 Feb 24
Current report (foreign)
11:35am
IRAN
feqa3eq
23 Feb 24
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
2:02pm
6-K
zozpip6
15 Feb 24
Current report (foreign)
12:09pm
SC 13G/A
ggsr3v1 0y03w
14 Feb 24
Sanofi / Amundi ownership change
3:57pm
SC 13G/A
a6y37l7mghfx6v1iftiv
13 Feb 24
Sanofi / DODGE & COX ownership change
1:55pm
SC 13G/A
rq974ulj
6 Feb 24
Sanofi / BlackRock ownership change
3:14pm
6-K
ea61j
2 Feb 24
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
1:21pm
6-K
pwa1fgsqnesof9mo
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
6-K
wvz7g 25w7o76
23 Jan 24
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
7:23am
6-K
voq28bzx
17 Jan 24
Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee
1:49pm
6-K
tsja1ng3vqf
27 Dec 23
Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
11:18am
6-K
vyn34dl0bt0aglkr17f5
20 Dec 23
Current report (foreign)
10:39am
F-6EF
zev5fs b2s6ujkx
18 Dec 23
Automatic registration for ADRs (foreign)
5:23pm
6-K
e2e7wg lv3
1 Dec 23
Current report (foreign)
12:19pm
SC 13G
9cuwrw n89dul39op
6 Nov 23
MeiraGTx / Sanofi ownership change
7:50am